These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27556369)

  • 1. Sometimes less is more in multiple sclerosis drug switching.
    Costa BK; Sato DK
    Arq Neuropsiquiatr; 2016 Aug; 74(8):605-6. PubMed ID: 27556369
    [No Abstract]   [Full Text] [Related]  

  • 2. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis.
    Fragoso YD; Alves-Leon SV; Becker J; Brooks JB; Correa EC; Damasceno A; Gama PD; Gama RA; Matta AP; Maciel EP; Winckler TC
    Arq Neuropsiquiatr; 2016 Aug; 74(8):650-2. PubMed ID: 27556377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.
    Piena MA; Heisen M; Wormhoudt LW; Wingerden JV; Frequin STFM; Uitdehaag BMJ
    J Med Econ; 2018 Oct; 21(10):968-976. PubMed ID: 29911917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
    Leurs CE; van Kempen ZL; Dekker I; Balk LJ; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
    Mult Scler; 2018 Oct; 24(11):1453-1460. PubMed ID: 28823223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal real-life comparison study of natalizumab and fingolimod.
    Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
    Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Fox E; Edwards K; Burch G; Wynn DR; LaGanke C; Crayton H; Hunter SF; Huffman C; Kim E; Pestreich L; McCague K; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):607-19. PubMed ID: 26265273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
    Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
    Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 11. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
    Capobianco M; di Sapio A; Malentacchi M; Malucchi S; Matta M; Sperli F; Bertolotto A
    Eur J Neurol; 2015 Mar; 22(3):585-7. PubMed ID: 24995482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
    Julian GS; Rosim RP; Carneseca EC; Rigolon J
    PLoS One; 2020; 15(3):e0229768. PubMed ID: 32119696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
    Warrender-Sparkes M; Spelman T; Izquierdo G; Trojano M; Lugaresi A; Grand'Maison F; Havrdova E; Horakova D; Boz C; Oreja-Guevara C; Alroughani R; Iuliano G; Duquette P; Girard M; Terzi M; Hupperts R; Grammond P; Petersen T; Fernandez-Bolaños R; Fiol M; Pucci E; Lechner-Scott J; Verheul F; Cristiano E; Van Pesch V; Petkovska-Boskova T; Moore F; Kister I; Bergamaschi R; Saladino ML; Slee M; Barnett M; Amato MP; Shaw C; Shuey N; Young C; Gray O; Kappos L; Butzkueven H; Kalincik T; Jokubaitis V;
    Mult Scler; 2016 Apr; 22(4):520-32. PubMed ID: 26199347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments.
    Al-Hussain F; Al-Salloum N; Alazwary N; Saeedi J; Howaidi S; Daif A
    J Comp Eff Res; 2017 Jul; 6(5):405-412. PubMed ID: 28699780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
    Iljicsov A; Pál Z; Simó M
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):197-205. PubMed ID: 26727724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis.
    Mukharesh L; Maloni H; Maiberger M; Chen W; Wallin M
    Clin Neurol Neurosurg; 2020 Aug; 195():105886. PubMed ID: 32470781
    [No Abstract]   [Full Text] [Related]  

  • 19. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.
    Laroni A; Brogi D; Milesi V; Abate L; Uccelli A; Mancardi G
    Mult Scler; 2013 Aug; 19(9):1236-7. PubMed ID: 23184503
    [No Abstract]   [Full Text] [Related]  

  • 20. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.